This is your moment.
About
Our High Throughput Screening (HTS) department spans 2 key sites In the UK & Netherlands. The department is responsible for delivery of both molecular target-based and phenotypic screening campaigns, helping to identify and qualify ‘hits’ for our client projects. Our department is led by industry experts with several years’ experience in the design and execution of Hit identification cascades – with groups and teams covering a range of different skillsets across biochemical and cellular screening techniques.
We have a strong team culture – with regularly sharing best practise and ensuring learning across our different sites to ensure a smooth and consistent client experience from a single joined-up global department.
What is HTS?
The short answer:
The most exciting area of drug-discovery!... HTS is the place where Biology & Chemistry first meet – working in this domain means that you get to be right at the forefront of the drug-discovery process (developing novel biological assays and identifying those initial putative ‘hit’ molecules which are the starting point of novel therapeutics
The longer answer:
CRL considers a project to be ‘HTS’ when many compounds (generally from 10K up to 1MM or beyond) are tested in a single screening activity. Client’s come to us to help them initiate their drug-discovery projects either through screening of our in-house chemical library or their own proprietary library. Our scientists work in close collaboration with our clients’ team to deliver a full hit identification program from inception to qualified and clustered starting points for on-going drug-discovery activities.
We use the below definition to describe HTS:
· HTS (diversity screening): A screening paradigm that enables coverage of broad chemical diversity in a single activity, with few target prerequisites. Hundreds of thousands of compounds can be screened in each experimental run, to deliver fast, efficient and (most crucially) consistent data.
· Phenotypic HTS: A diversity screening approach which employs a functional cellular assay as the primary screen (ideally in a disease-relevant cellular model). In this instance it will be unclear as to MOA of the compounds that appear as ‘hits’
Our CADD & Predictive Sciences team are core members of drug discovery optimisation programs within Charles River. Applying computational modelling expertise in partnership with medicinal chemistry and structural biology colleagues makes a real impact on the progression of drug discovery projects from hit identification through to candidate nomination.
By joining our CADD & Predictive Sciences team you will have the opportunity to work with a diverse range of organisations across the globe, from charitable organisations and academic groups to biotech and major pharma, helping to bring much needed medicines to patients faster.
You will work on a wide range of drug discovery projects across different therapeutic areas and target classes at all stages of the drug discovery process, and you will have the opportunity to work with world class scientists in different disciplines from across the wider Charles River organisation. With a strong culture of personal development, we will support you every step of the way as you progress your career at Charles River.
We believe that no other drug discovery organisation can offer such a rich and diverse array of development opportunities as you will find at Charles River.